Testosterone is under clinical development by Viramal and currently in Phase III for Female Hypoactive Sexual Desire Disorder. According to GlobalData, Phase III drugs for Female Hypoactive Sexual Desire Disorder have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Testosterone’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Testosterone overview

Testosterone Bi-Gel (TestoCream) is under development for the treatment of male hypogonadism and female androgen deficiency syndrome. It is a cream formulation of testosterone, which is administered through the transdermal route. It is a stable bi-phasic gel system with very low alcohol content. It is a semi-solid dosage form based on the intimate mixture of an oleogel and an aqueous gel. BiGel products are based on a surfactant-free formula and can accommodate both lipophilic and water-soluble drugs. It is developed based on ViraDerm transdermal technology.

Viramal overview

Viramal is a pharmaceutical and health care company that provides women’s health products. The company offers discovery and development of therapeutics to improve women’s health. Its products portfolio includes elegant vaginal moisturizer that is used for the treatment of vaginal atrophy and prevention of local infections through pH modification; and testocream and estrogen therapy, among others. Viramal’s products are used in the treatment of menopausal hormone therapy, fertility, contraception and sexual health. The company also provides prescription drugs and non-prescription drugs. It has its operations in the UK and the US. Viramal is headquartered in London, England, the UK.

For a complete picture of Testosterone’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.